PTC Therapeutics, Inc.
2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders

Last updated:

Abstract:

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of .alpha.-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.

Status:
Grant
Type:

Utility

Filling date:

30 Mar 2021

Issue date:

16 Nov 2021